Estimating Age-Specific Cumulative Incidence for the 2009 Influenza Pandemic: a Meta-Analysis of A(H1N1)pdm09 Serological Studies from 19 countries

Maria D. Van Kerkhove1,2*, Siddhivinayak Hirve1*, Artemis Koukounari2 and Anthony W. Mounts1† for the H1N1pdm serology working group†‡

1 Global Influenza Programme, WHO Geneva, Switzerland
2 MRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, UK

†Members of the H1N1pdm Serology Working Group Include:*α

‡Corresponding Author:
Anthony W. Mounts
Global Influenza Programme
World Health Organization
Geneva, Switzerland
Email: mountsa@who.int
Telephone: +41227911062

Citation: Van Kerkhove MD, Hirve S, Koukounari A and Mounts AW., for the H1N1pdm serology working group. (2013) Estimating Age-Specific Cumulative Incidence for the 2009 Influenza Pandemic: a Meta-Analysis of A(H1N1)pdm09 Serological Studies from 19 countries, Influenza and Other Respiratory Viruses. Published online 21 January 2013. doi: 10.1111/irv.12074. [Epub ahead of print]

Key Words: A(H1N1)pdm09, H1N1pdm, seroprevalence, cumulative incidence, cross-reactive antibodies

*These authors contributed equally to this work.

The opinions expressed in this article are those of the authors and members of the working group and do not necessarily reflect those of the institutions or organizations with which they are affiliated.

αSee affiliations of working group members at the end of the manuscript.
Abstract

**Background:** The global impact of the 2009 influenza A(H1N1) pandemic (H1N1pdm) is not well understood.

**Objectives:** We estimate overall and age-specific prevalence of cross-reactive antibodies to H1N1pdm virus and rates of H1N1pdm infection during the first year of the pandemic using data from published and unpublished H1N1pdm seroepidemiological studies.

**Methods:** Primary aggregate H1N1pdm serologic data from each study were stratified in standardized age groups and evaluated based on when sera were collected in relation to national or sub-national peak H1N1pdm activity. Seropositivity was assessed using well described and standardized hemagglutination inhibition (HI titers ≥32 or ≥40) and microneutralization (MN≥40) laboratory assays. The prevalence of cross reactive antibodies to the H1N1pdm virus was estimated for studies using sera collected prior to the start of the pandemic (between 2004-April 2009); H1N1pdm cumulative incidence was estimated for studies in which collected both pre- and post-pandemic sera; and H1N1pdm seropositivity was calculated from studies with post-pandemic sera only (collected between December 2009-June 2010).

**Results:** Data from 27 published/unpublished studies from 19 countries/administrative regions—Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, United Kingdom, United States and Vietnam—were eligible for inclusion. The overall age-standardized pre-pandemic prevalence of cross-reactive antibodies was 5% (95%CI 3-7%) and varied significantly by age with the highest rates among persons ≥65 years old (14% 95%CI 8-24%). Overall age-standardized H1N1pdm cumulative incidence was 24% (95%CI 20-27%) and varied significantly by age with the highest in children 5-19 (47% 95%CI 39-55%) and 0-4 years old (36% 95%CI 30-43%).

**Conclusions:** Our results offer unique insight into the global impact of the H1N1 pandemic and highlight the need for standardization of seroepidemiological studies and for their inclusion in pre-pandemic preparedness plans. Our results taken together with recent global pandemic respiratory-associated mortality estimates suggest that the case fatality ratio of the pandemic virus was approximately 0.02%.
Author Summary

This study represents the combined work and collaboration of influenza researchers from more than 27 different research groups around the world and is the first of its kind to use original data to produce a summary estimate from a global perspective of the proportion of the population that was infected during the first year of the influenza pandemic of 2009. Our analysis includes original serologic data from several low- and middle-income countries including China, India, Iran, Vietnam, and Reunion Island and high-income countries, including Australia, Canada, Finland, France, Germany, Hong Kong SAR, Italy, Japan, Netherlands, New Zealand, Norway, Singapore, United Kingdom, and the United States.

This work provides critical insight into the underappreciated impact and severity of the pandemic and our results are of great value in planning and preparing for the next pandemic. Age-specific cumulative incidence rates are critical parameters used by public health decision makers and mathematical modellers in planning for and responding to a pandemic and provides accurate denominator estimates to the calculate a key parameter - the case-fatality ratio. Together with recent\(^1\) and forthcoming\(^2\) estimates of H1N1pdm mortality – the numerator of the case fatality ratio – and our summary cumulative incidence results, we suggest that the case fatality ratio of the pandemic virus was approximately 0.02% providing insight into the severity of the 2009 influenza pandemic globally.
Introduction

Soon after detection of the novel pandemic influenza A(H1N1)2009 virus (H1N1pdm) in Mexico and
the United States in April 2009\(^3\), countries across the globe began reporting laboratory confirmed
H1N1pdm cases to the World Health Organization (WHO)\(^4\). However as case numbers increased,
laboratories were overwhelmed with demand for testing. WHO responded with new guidance in
June 2009 asking that countries report the first cases detected in a country, that testing focus on
fatal and severe cases, and for countries to only report fatal cases to WHO\(^5\). As a result, by the time
the pandemic was declared over in August 2010\(^6\), reported numbers of cases and deaths (<1 million
and >18,449\(^7\), respectively) reported to WHO represented only a small fraction of the true burden of
infection and mortality due to H1N1pdm.

Even in well-resourced countries, the very large numbers of H1N1pdm cases, the non-specificity of
clinical case definitions for influenza, and finite testing capacity means that incidence cannot be
estimated from case-based surveillance. This information is critical to understanding the overall
morbidity, mortality and population-level severity of the H1N1pdm virus as it serves as the
denominator for the estimation of severity measures. Along with population-level surveillance to
capture numerators (i.e., H1N1pdm cases, hospitalizations, deaths), representative serological
studies are designed to collect denominator data (i.e., infections) that can be used to estimate
severity parameters such as the case fatality ratio (i.e., CFR, the total number of H1N1pdm deaths
divided by the total number of H1N1pdm infections) and hospitalization ratios (number of H1N1pdm
hospitalizations divided by H1N1pdm infections). Thus analysis of serological data can provide
accurate measures of incidence, reduce the uncertainty around severity assessment, and help
inform the appropriate intensity and targeting of mitigation policies.\(^8\)-\(^10\).

As well as estimating the proportion of the population infected by a particular virus, data from
seroepidemiological studies can provide insights into age-specific and regional trends in incidence
and cross-protective immunity, which are important to characterize the infectivity of a new virus,
identify key target groups for interventions and for developing mitigation measures.\(^8\)-\(^11\) Insight into
cross-protective (or partial) immunity acquired from exposure to other influenza strains or
vaccination is of particular scientific interest. Knowing what proportion of the population had
antibodies before the first wave and how this immunity affected subsequent circulation of the virus
provides valuable information for understanding the transmission dynamics of influenza pandemics
more generally.
A number of early seroepidemiological studies using residual sera collected prior to the start of the H1N1pdm pandemic were conducted within months of identification of the H1N1pdm virus to assess the level of pre-existing immunity in the population by age, quickly followed by investigations from a number of countries to estimate the proportion of the population infected with the H1N1pdm virus. Together with early investigations elucidating age-specific clinical attack rates and transmission characteristics of the new virus, these studies provided critical input into and reduced uncertainty around national and global policy decisions. Numerous seroepidemiological studies have subsequently been published, but the comparison and direct interpretation of the results of serological studies is difficult due to the varied epidemiological methods used to collect sera, the heterogeneity in the populations under study, variation in laboratory assays used, and criteria for seropositivity.

The objective of this study is to bring together all available original serological data in a standardized format from H1N1pdm seroepidemiological studies to estimate the proportion of the population with cross-reactivity antibodies to H1N1pdm prior to the start of the pandemic and to estimate age-specific cumulative incidence of H1N1pdm during the first year of the pandemic. This study builds upon the findings of Kelly et al. by including a number of additional H1N1pdm serologic studies conducted from a number of additional countries since this publication. Combined with what is known about morbidity and mortality of the pandemic virus around the world, these estimates provide a better sense of the overall global impact of the H1N1 pandemic.

**Methods**

An extensive literature search for H1N1pdm serological studies was conducted using a keyword-based computerized search of the National Library of Medicine through PubMed. The search was limited to all H1N1pdm seroepidemiological studies published by 1 January 2012. Articles with the MeSH keywords: human influenza, pandemic, sero-incidence and seroprevalence, in their titles or abstract were reviewed for eligibility for inclusion. The references cited in screened articles were further inspected by SH and MDVK to identify additional relevant studies (any discrepancies were discussed with AWM; Figure 1a). In addition to published studies, the WHO Global Influenza Programme contacted researchers known to be conducting serological studies from a comprehensive list of planned and ongoing H1N1pdm serological studies compiled and maintained by WHO. Additionally, a further effort was made to identify unpublished studies by contacting experts and known influenza researchers by searching influenza conference proceedings and country surveillance agency reports. Researchers of unpublished studies were asked to share their study methodology (further details below) and preliminary results to allow assessment for inclusion.
As with published studies, unpublished data were also used only if data were available by 1 January 2012.

**Inclusion/Exclusion criteria**

Inclusion criteria: Published and unpublished studies, which measured overall and age-stratified antibody titers against H1N1pdm 2009 influenza virus by well described and standardized hemagglutination inhibition (HI) and microneutralization (MN) laboratory assays were included. Briefly, seropositivity was assessed as assay HI titres ≥32 or MN assay ≥40. Additionally, serological studies which measured cross-reactive antibodies to H1N1pdm influenza virus in sera collected prior to the start of the 2009 pandemic were included to quantify age stratified pre-existing cross-reactive antibody levels in populations. To be included, authors of individual studies were required to provide results in harmonized age groups (0-4; 5-19; 20-44; 45-64 and ≥65 years old) and additional details about their study population (e.g., specific start and end dates for sera collection, sample size in each age group, assay and criteria for seropositivity, description(s) of study populations from which sera was used, specific location(s) of residence of subjects providing sera, and use of seasonal and pandemic vaccination among included sera, if possible). When use of H1N1pdm vaccine was available in individual studies, we asked authors to provide results among unvaccinated persons only.

Exclusion criteria: Clinical vaccine trials were excluded, as were serological studies of avian and seasonal (H1N1 or H3N2) influenzas. Additionally, studies or data within studies of populations in closed settings (i.e., military facilities, schools) or among specific populations only (e.g., HIV infected individuals or pregnant women) were excluded. Finally, studies which included only H1N1pdm vaccinated individuals were excluded.

**Data abstraction, synthesis and statistical methods used for metanalysis**

Data from included studies were categorized based on when sera were collected in relation to national, or sub-national where available, 2009-2010 virologic H1N1pdm activity¹⁸ (Figure 1b; categories: pre-pandemic sera, pre- and post-pandemic sera and post-pandemic sera only). Studies which only collected sera during the peak of H1N1pdm virologic activity were excluded from the analyses (Figure 1b, shaded area). For all three different set of analyses: overall and age-specific prevalence of cross reactive antibodies to the H1N1pdm virus using pre-pandemic sera, overall and age-specific cumulative incidence using studies with both pre- and post-pandemic sera and overall and age-specific seroprevalence using studies with post-pandemic sera only, we used random effects
(at the study level) logistic regressions to obtain pooled overall and age specific estimates as well as to take into account the heterogeneity of results between studies.

A database was created (by SH and MDVK) to collate extracted information from each study including: country of study, author and year of publication, laboratory assay(s) used, cut-off value used for determining seropositivity, description of study population from whom sera was collected, period(s) when sera were collected, sample size, proportion seropositive with 95% confidence intervals, timing of the national peak pandemic activity for the relevant country according to data reported to FluNet18, timing of H1N1pdm vaccination campaign for the country, use of seasonal vaccine among study population (if available), and difference between timing of sera collection and H1N1pdm peak virologic activity (in weeks). Because different studies used different age categories for reporting seropositivity results in their individual publications, we requested all researchers to share their seropositivity results for five age categories (0-4; 5-19; 20-44; 45-64 and ≥65 years old) to ensure comparability. These age categories were chosen based on differences in the epidemiology, and reported clinical severity of the disease in these age groups19. Overall pooled estimates were age-adjusted using age-specific population estimates from the UN20. To evaluate seroprevalence levels over time, we explored age-specific post-pandemic seroprevalence versus the difference in timing of sera collection and the national peak of H1N1pdm virus activity.

Pre-pandemic sera to estimate prevalence of cross-reactive antibodies to the H1N1pdm virus

All sera collected prior to April 1 2009, regardless of study design, were classified as pre-pandemic sera for which baseline overall and age-specific cross reactive antibodies to the H1N1pdm virus were estimated (Figure 1b). We modeled overall and age-specific pre-pandemic prevalence of cross-reactive antibodies from studies with sera collected prior to April 2009 (Figure 1b, area indicated as time period A) and studies that included sera collected prior to widespread community transmission (see Figure 1b, time period B). We then explored, in addition to other possible causes of heterogeneity (described below), if study timing explained any of differences (i.e. whether the pre-pandemic prevalence of cross-reactive antibodies differed between studies conducted at time period A vs. B). Only studies which analyzed seropositivity using HI were included in pre-pandemic analyses. Details of the included studies are provided in Table S1 in the Supplemental Information.

Pre- and post- pandemic sera to estimate cumulative incidence

For studies which had both pre- (Figure 1b time period A or B) and post- pandemic sera (Figure 1b, time period C or D) according to the national or sub-national period of H1N1pdm virus circulation, overall and age-specific cumulative incidence was calculated for each study by taking the difference
in seroprevalence. In included studies, sera were collected twice from the same subject (paired sera from longitudinal studies) or twice in the same population but from different individuals (unpaired sera from cross-sectional studies) before the start of the pandemic and after the pandemic was over. Studies which analyzed seropositivity by HI and MN were included in incidence calculations. Details of the included studies are provided in Table S2 in the Supplemental Information.

Post-pandemic sera to estimate H1N1pdm seroprevalence

Finally, we modeled and provided pooled overall and age-specific H1N1pdm seroprevalence from post-pandemic sera, i.e., sera collected during time periods which coincided with a decline in national or sub-national H1N1pdm transmission (Figure 1b, time period C) or when transmission ceased (Figure 1b, time period D). Only studies which analyzed seropositivity using HI were included in post-pandemic analyses. Details of the included studies are provided in Table S3 in the Supplemental Information.

Meta-regression

We explored differences in the outcomes listed above of all three sets of analyses, by adjusting for one covariate at a time in the random effects logistic regressions. Such models allow for within and between study variation to be included in the estimated coefficients. The covariates considered in the relevant univariable random effects logistic regressions were: study timing for the pre- and post-pandemic single sera analyses (i.e., we examined if there were differences: 1: for the pre-pandemic studies, between studies conducted at time period A and B in Figure 1b, and 2: for the post-pandemic single sera studies, between studies conducted at time period C and D in Figure 1b respectively); assay (HI≥1:32; HI≥1:40; MN≥1:40; for estimates of H1N1pdm cumulative incidence, only); subject type; country and geographic region of sera collection; if H1N1pdm vaccination was used in the included countries; and population density at the national level\(^2^1\).

Results

Included studies

Seventy-four articles were identified for title and abstract review and 32 full text articles were retrieved and reviewed (Figure 1a). Twenty-seven studies, including 8 unpublished studies (at the time of data collection) were included in the meta-analysis (Table 1). Of those, 19 studies from 15 countries included pre-pandemic sera in which overall and age-specific prevalence of cross-reactive antibodies were estimated\(^2^2\)-\(^4^0\) (details of included studies are shown in Table S1 in the Supplemental
Information); 12 studies from 11 countries contained both pre-and post pandemic in which overall and age-specific H1N1pdm cumulative incidence were estimated\textsuperscript{22,23,29-34,38,39,41-43} (Table S2 Supplemental Information); and 10 studies from 9 countries contained post-pandemic sera in which overall and age-specific H1N1pdm seroprevalence was estimated\textsuperscript{35-37,44-50} (Table S3 Supplemental Information).

In total, our analysis was based on approximately 90,000 serological samples from 19 countries and/or administrative regions, including Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, the United Kingdom (UK), the United States (US) and Vietnam (Figure 2)\textsuperscript{9,22-28,30-32,34-39,41,42,44,46-53}. Pre-pandemic seroprevalence data were available from Chinese Taipei\textsuperscript{54}, but excluded from the pooled results because results were only available by MN. Pre- and post-pandemic sera from Greece was excluded from the cumulative incidence results because seropositivity was analyzed by enzyme-linked immunosorbent assay (ELISA), a novel method developed by the researchers and not fully validated\textsuperscript{55}.

**Pre-pandemic prevalence of cross-reactive antibodies**

The pre-pandemic prevalence of cross-reactive antibodies were estimated from pooling serological data from 15 countries from 19 studies (n sera = 15,476). The overall age-adjusted pre-pandemic prevalence of elevated cross-reactive H1N1pdm antibodies from was 5% (95%CI 3-7%; Table 1; Figure 3a). Prevalence increased with age (Figure 4a; 0-4 years old 1% [0.3-4%], 5-19 years old 4% [1-9%], 20-44 years old 5% [3-8%], 45-64 years old 5% [2-9%]) and was highest in subjects 65 years and older (14% [8-24%]). Overall, there were significant differences in prevalence by region, with individuals from Asia less likely and subjects from one site in Africa (Reunion Island) more likely to have cross-reactive antibodies to H1N1pdm when compared with Europe (OR=0.098 95%CI 0.01-0.9); OR=9.2 95%CI 1.9-43.8), respectively). Subjects from one site in Africa also had higher seroprevalence among 5-19 (OR=14.2 95%CI 1.2-174.9), 20-44 (OR=6.9 95%CI 3.3-14.4), 45-64 (OR=21.4 95%CI 4.2-110.0) and ≥65 (OR=17.0 95%CI 2.3-127.2) year old age groups when compared to individuals from Europe in the same age groups. Subjects 20-44 years old from Asia had lower seroprevalence when compared to Europe (OR=0.20 95%CI 0.1-0.4). Subjects from one study of rural households (Vietnam) had lower overall pre-pandemic seroprevalence than outpatients (OR=0.06 95%CI 0.004-0.8). There were no significant differences in pre-pandemic seroprevalence and any other covariate under investigation.
Cumulative incidence of pandemic influenza infection

Data used to estimate age-specific cumulative incidence was available from 11 countries and 12 studies (Table 1; Table SI 2). The overall age-adjusted cumulative incidence of H1N1pdm infection based on the difference between pre- and post-pandemic seroprevalence was 24% (95%CI 20-27%, Figure 3b) and varied significantly by age (Figure 4b). The highest age-specific incidence was found among children 5-19 years old (46% [36-56%]), followed by 0-4 years old (37% [30-44%]) and decreased by age from 20 years old and older (20-44 years old 20% [13-26%], 45-64 years old 14% [9-20%]). The lowest incidence was found in those ≥65 years old (11% [5-18%]).

There were significant associations found between incidence and region and subject type in the overall estimate indicating that overall cumulative incidence was 28% lower (95%CI 7.7-48.4) in Asia when compared to Europe and 23% lower (95%CI 3.1-42.7) in subjects from rural households (Vietnam) compared to countries sampling from outpatients. Samples from subjects 5-19 years old from Asia and Oceana had lower cumulative incidence that samples from Europe in the same age group (29% [95%CI 15.8-41.9] lower, 21% [95%CI 3.1-39.3] lower, respectively). Countries which may have included persons between the ages of 5-19 and 20-44 vaccinated with the pandemic vaccine in their sampled population had higher cumulative incidence than countries that excluded H1N1pdm vaccinated persons in these same age groups (19% [95%CI 3.4-33.8]higher, 15% [95%CI 3.1-26.1]higher, respectively). When we exclude the two countries, which suggested that a significant proportion of their study populations’ seroprevalence may be due to vaccination (Norway34 and the US39), rather than natural infection, the overall pooled cumulative incidence is 21% (95%CI 18-25; see Figure 1 in supplemental Information) compared to 24% (95%CI 20-27%).

Post-pandemic seroprevalence

Post- pandemic seroprevalence was estimated by pooling data from 9 countries from 10 studies (n sera = 52,479; Table 1). The overall age-adjusted H1N1pdm seroprevalence was 32% (95%CI 26-39%; Figure 3c). From age 5, seroprevalence generally, though not significantly, decreased with age (Figure 4c) and decreased, not significantly, across all groups with increasing time interval between sera collection and peak in influenza virus activity (data not shown). There were no significant associations between overall seroprevalence and any covariate examined. However, for the 0-4 year old age group, a lower proportion sampled after the epidemic wave was over (Figure 1b, time period D) were seropositive compared with sera collected during the decline of the epidemic (Figure 1b, time period C; OR=0.16 95%CI 0.04-0.6). In addition, for the 0-4 year old age group, countries which may have included persons vaccinated with the pandemic vaccine in the sampled population had
lower seroprevalence than countries that excluded H1N1pdm vaccinated persons (OR=0.21 95%CI 0.06-0.8).

Discussion

Our study is the first to gather and analyze primary H1N1pdm serologic data in standardized age groups from countries/administrative regions across the world. Our results suggest that approximately 20-27% of the populations in the included countries were infected with H1N1pdm virus during the first year of circulation. Incidence was highest in the 5-19 year age group, where approximately 46% (95% CI 36-56%) were infected, and lowest in the ≥65 age group, where approximately 11% (95% CI 5-18%) were infected. Although, as expected, there was some local within-country variation in infection rates as demonstrated by individual studies, we found consistency in age-specific cumulative incidence estimates across countries. This consistency in estimated infection rates by age group between countries may have been strengthened in part because we consistently categorized our sera based on timing of collection in relation to peak H1N1pdm viral activity in each country. Assuming that the cumulative incidence in the countries included in our studies is similar to the rest of the world for which little no data exist and if the global mortality estimates produced by two research groups\textsuperscript{1,2} are confirmed by other studies, this would place the CFR for H1N1pdm at less than 0.02%.

Our results are consistent with our estimates of H1N1pdm seroprevalence using post-pandemic sera and with other H1N1pdm seroprevalence studies recently or not yet published from Iceland, Mexico, Chinese Taipei, India, Mongolia, Mali\textsuperscript{54,56-59}, Laos, Djibouti, and Bolivia (CoPanFlu-International consortium unpublished data, personal communication from X de Lamballerie), with a study from Greece with pre- and post-pandemic sera that was excluded from our analyses\textsuperscript{55}, but are slightly higher than the overall estimated cumulative incidence found in one analysis\textsuperscript{17}. This may be because our study includes a number of additional middle and low countries who conducted serologic studies since this analysis was published and because we excluded studies which focused on specialized populations\textsuperscript{17}). Additionally, the age-specific trends we found in our cumulative incidence results are consistent with studies which measured cumulative incidence as a 4 fold increase in titers among paired sera\textsuperscript{36,42,60} and similar to studies which measured age-specific secondary attack rates using RT-PCR.\textsuperscript{61,62}

In the analyses of pre-pandemic data, we found increasing levels of cross-reactive antibodies to H1N1pdm virus with age, although there were differences in these patterns by region. For example, older individuals in some Asian countries had lower levels of cross-reactive antibodies prior to
widespread circulation of the pandemic strain than did individuals in other regions. However, this was not a universal finding for all Asian countries, and may be a reflection of the age-groups we chose in this meta-analysis because we collapsed elderly age categories into a single unit (≥65 years of age): some studies observed differences among the elderly (>65 years old) versus very senior individuals (i.e., >80 years old, e.g., 25,41,54,63). We note that regional differences did not persist when: only looking at cumulative incidence; from studies in which two sets of sera from one population were tested in the same laboratory using the same methodology; or in post-pandemic seroprevalence. Therefore, given the small numbers of studies in individual regions, these patterns may reflect differences in laboratory methodology. However, this does not rule out the possibility that some serologic assays fail to identify antibodies in older individuals, or reflect antibodies amongst older individuals in countries without high routine seasonal influenza vaccination coverage64. Differences in laboratory methodology rather than real differences in pre-existing immunity would also explain the observation that reported cumulative incidence was not higher in ≥65 year olds in Asia where pre-pandemic seroprevalence was found to be lower65. We also observed low level pre-pandemic seropositivity in children (<5%) and adolescents (<10%) in some countries, which may again be due to assay differences between laboratories.

There are a few factors that may affect the accuracy of our estimates. The inherent limitations of combining results from influenza serologic studies have been widely discussed 12,16,66 and could have an impact on the accuracy of our estimates. Based on our analyses, we strongly support the recommendations to standardize influenza seroepidemiological studies both in terms of epidemiologic and laboratory methods. In addition, declining antibody levels over time in some of the populations studied and the fact that not all laboratory confirmed H1N1pdm patients seroconvert 37,67-70 could have resulted in our results slightly underestimating the true incidence. We found limited evidence of a decline in the proportion seropositive over time when looking at the timing of post-pandemic sera collection in relation to the peak in H1N1pdm virus activity (data not shown). We found conflicting results with respect to the impact of vaccination in our cumulative incidence estimates and post-pandemic estimates. Because of this and because vaccine coverage in most of the included countries had reached little of the population at the time sera were collected (e.g., in the United States39), and the observed increase was not in age groups targeted for vaccination, we believe that the H1N1pdm vaccination has had little impact on our overall cumulative infection and seroprevalence estimates results. When we excluded studies that suggest that seroprevalence may be due to vaccination34,39, rather than natural infection, the overall pooled cumulative incidence reduced slightly.
Finally, we were unable to include serological data in our pooled estimates from all regions of the world – notably from mainland Africa and Latin America, where to our knowledge, no H1N1pdm09 seroprevalence data exists. Despite this, however, we believe that H1N1pdm incidence may have been similar in all parts of the world because reported mortality rates and published reports of influenza activity in Latin America and Africa were similar to those reported in Europe and North America\textsuperscript{71-73}, and to those reported in the countries included in our study. The lack of H1N1pdm morbidity, mortality and serological data from Africa\textsuperscript{74}, however, leaves substantial uncertainty in that region of the world. Because of the limited number of countries included in our overall and age-specific cumulative incidence estimates, we were unable to resolve differences between temperate and tropical counties. While data from Vietnam and Hong Kong were included and the incidence estimates-- incidence in Vietnam was significantly lower possibly indicating differences in incidence in rural areas, and incidence from Hong Kong was consistent with incidence from the temperate countries included in our analysis--we are missing serologic data from many other low and middle income tropical and sub-tropical countries.

Our analysis demonstrates that approximately 24% of the populations of countries for which there are data were infected during the first wave of the pandemic, with incidence reaching 50% in school-age children. This meta-analysis offers a unique insight into the global impact of the 2009 influenza pandemic in its first year and highlights the need for seroepidemiological studies to be standardized and included in pre-pandemic preparedness plans. Together with estimates of global mortality\textsuperscript{1,2}, our data has improved our understanding of the behavior and impact of the influenza pandemic of 2009.
### Table 1. Characteristics of included studies for each of the age-specific and age-standardised pooled estimates

<table>
<thead>
<tr>
<th>Description of sera included in estimate</th>
<th>Age-specific H1N1pdm cross-reactive antibodies</th>
<th>Age-specific H1N1pdm cumulative incidence</th>
<th>Age-specific H1N1pdm seroprevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia, Canada, China, Finland, France, Germany, India, Italy, Japan, New Zealand, Norway, Reunion Island, Singapore, UK, USA (15)</td>
<td>Studies, which included pre-pandemic sera</td>
<td>Studies, which included both pre-and post-pandemic sera</td>
<td>Studies, which included post-pandemic sera (only)</td>
</tr>
<tr>
<td>Source of sera (n countries)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Australia, Canada, France, Germany, Iran, Netherlands, Reunion Island, Singapore, UK, USA (9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of studies included in estimates</td>
<td>19</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>Number of sera samples included in analyses</td>
<td>15,476</td>
<td>Pre-pandemic sera = 9,910</td>
<td>52,479</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-pandemic sera = 14,228</td>
<td></td>
</tr>
<tr>
<td>Assays used and criteria for seropositivity</td>
<td>HI ≥1:32‡ or HI ≥1:40</td>
<td>HI ≥1:32; HI ≥1:40; MN ≥1:40</td>
<td>HI ≥1:40†</td>
</tr>
<tr>
<td>Overall age-standardized pooled estimate (95% CI)</td>
<td>5% (3-7%)</td>
<td>24% (20-27%)</td>
<td>32% (26-39%)</td>
</tr>
</tbody>
</table>

See Tables S1-S3 in the supplemental information for details of individual studies.

HI = Hemagglutination inhibition
MN = Microneutralization assay
‡Harelid et al 2010 and Kawaoka et al 2011 only; all other studies used HI ≥1:40 as criteria for seropositivity
†All studies in H1N1pdm seroprevalence estimates used HI ≥1:40 as criteria for seropositivity
Figures

74 articles listed in PubMed
11 unpublished studies identified through other sources

42 articles excluded
  • Review article
  • Focus on avian flu subtype
  • Focus on seasonal flu subtype
  • Focus on outbreak investigation of specialized populations
  • Focus on special populations

3 unpublished studies excluded
  • Age-specific results not available

32 published/unpublished articles reviewed in depth

27 published/unpublished papers included

5 published studies excluded
  • Age specific results not available
  • Excluded based on laboratory methods

Figure 1a. Review Process of Published and Unpublished H1N1pdm Serologic Literature Search

Figure 1b. Example of the Characterization of Timing of Sera Collection in Relation to National H1N1pdm Virus Activity

N.B. Characterization of sera timing was conducted using the national, or sub-national when available, epidemic curve separately for each country that provided serological data. Time period A indicates the time period prior to the reporting of the first H1N1pdm cases in North America and start of the 2009 influenza pandemic. Time period B indicates the time period after the H1N1pdm virus was identified in North America, but before wide-spread circulation of the virus occurred in each country. This assessment was made for each individual country or sub-national geographic area if sub-national virologic data were available. Time period C indicated the time after the national or sub-national peak in H1N1pdm virologic activity was over, but not completely back to baseline levels. Time period D indicates the national or sub-national time when H1N1pdm virus circulation was clearly over. Shaded area indicates example of peak H1N1pdm virologic activity. Studies which collected sera during peak activity were excluded from the analyses.
Figure 2 Geographic Distribution of Included Study Populations
Figure 3 Cumulative Incidence of H1N1pdm Infection in Studies with Pre- and Post Pandemic Sera Collection

Legend: Each dot represents the unadjusted point estimate with 95% confidence bounds for a study that provided data from all age groups. Individual study estimates are unadjusted; the pooled estimate is age-adjusted. There was heterogeneity in the overall rates variance estimates for the random effects for the a) pre-pandemic overall estimates a) $p=0.024$ and post-pandemic seroprevalence rates c) $p=0.09$; and the $I^2$ for the overall cumulative incidence rates b) = 98.1%.
Figure 4 Age-specific (a) prevalence of cross-reactive antibodies from baseline pre-pandemic sera, (b) cumulative incidence of H1N1pdm infection using pre- and post-pandemic sera and (c) H1N1pdm seroprevalence from post-pandemic sera.

Legend: Point estimates indicates pooled estimate and lines represent relevant 95%CI. Each line represents unadjusted age specific results from individual studies. See Tables S1-3 for studies included in each estimate.
Acknowledgements

The authors would like to thank the many subjects who contributed in the individual studies and for the countries who were willing to share their prepublication results to be included in this study. The authors would like to thank the following for their contributions to the initial studies in which data were shared for this meta-analysis: Ange Bissielo, Adam Meijer, Alessia Ranghiasci, Alexia Kieffer, Allison McGeer, Anette Kilander, Anne Kelso, Antoine Flahault, Anu Rebbapragada, Armelle Degeorges, Azzedine Assal, Beth Lowcock, Brian O’Toole, Brunhilde Schweiger, Bruno Lina, Caitlin Johnson, Camille Achonu, Carmen Yue, Ching-Chuan Liu, Chung-Ming Chang, Corey J. Crevar, Danielle Iuliano, David Irving, Dominic Dwyer, Don Willison, Donald M. Carter, Donald S. Burke, Emanuele Montomoli, Gérard Krause, Giulia Lapini, Graham Mackereth, Grethe H Krogh, Ian Johnson, Jacco Wallinga, Jacqueline Willmore, Jean-Paul Guthmann, Johan HJ Reimerink, Jonathan B Gubbay, Julie Foisy, Kate Goodin, Kathy Hancock, Klaus Stark, Laura Rosella, Linda Hueston, Maria Cristina Rota, Maria Grazia Caporali, Marianne AB van der Sande, Marie LaFreniere, Mariken van der Lubben, Marion Koopmans, Michael Baker, Michael Höhle, Michel Thamm, N Lapidus, Nicolas Salez, Panos Katerelos, Peter FM Teunis, Pierre Tiberghien, Rhonda Owen, Richard Beasley, Richard Hopkins, Sally Roberts, Sandra Waaijenborg, Shelley L Deeks, Silke Buda, Silvia Declich, Simona Piccirell, Steven Ostrof, Stewart Reid, Susanne G Dudman, Sylvie van der Werf, Tim Wood, Tony Mazzulli, Torstein Aune, Travis S Hottes, Valeria Alfonsi, Virginia Hope and YK Gurav. The authors would also like to thank the Health Policy Research Center in Iran and specifically, Dr K.B Lankarani.

The authors would also like to acknowledge colleagues who shared data that did not meet our inclusion criteria: Theodore Tsai, Xiao-Feng Liang, Yu Wang, Fengcai Zhu, Laura Thompson and Salah Mahmud.

The authors would like to thank Ben Cowling and Malik Peiris for his insight and advice on the analysis and interpretation of results.

MDVK, AK, CAD, and NMF acknowledge funding from the Medical Research Council UK and the Bill and Melinda Gates Foundation (MDVK, NMF). AK is currently supported by an MRC Population Health Scientist Fellowship. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Contributions of Authors:

Members of the H1N1pdm Serology Working Group

Regina Allwinn
Institute for Medical Virology
JW Goethe University Hospital
60596 Frankfurt am Main
Germany

Don Bandaranayake
Institute of Environmental Science and Research
National Centre for Biosecurity and Infectious Disease
Upper Hutt, New Zealand

Antonino Bella
National Centre for Epidemiology, Surveillance and Health Promotion
National Institute of Health (Istituto Superiore di Sanità ISS)
Viale Regina Elena, 299
00161 Rome Italy

Angie Bone
Institut de Veille Sanitaire (French Institute for Public Health Surveillance), 12 rue du Val d’Osne
94415 Saint-Maurice Cedex, France & EPIET, European Programme for Intervention Epidemiology, ECDC, Stockholm

Fabrice Carrat
UMR-S 707, Épidémiologie, Modélisation, Systèmes d’information
Faculté de médecine Pierre et Marie Curie
27, rue Chaligny
75571 Paris

Mandeep S Chadha
National Institute of Virology
20-A, Dr Ambedkar Road
Pune 411001 India

Mark Chen
Department of Epidemiology and Public Health, National University of Singapore & Department of Clinical Epidemiology, Tan Tock Seng Hospital
Singapore

Chia-Yu Chi
National Institute of Infectious Diseases and Vaccinology
National Health Research Institute
No. 367 Sheng-Li Road
Tainan, Taiwan 704

Chad M. Cox
Respiratory Diseases Branch, NCIRD,
US Centers for Disease Control and Prevention
1600 Clifton RD NE, MS C-25
Atlanta, GA 30333, United States

Michelle Cretikos
Public Health Intelligence Branch
Centre for Epidemiology and Evidence
NSW Ministry of Health
73 Miller St North Sydney NSW 2060
Australia

Natasha Crowcroft
Department of Surveillance and Epidemiology, Public Health Ontario, Toronto, Ontario, Canada,
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Jeffery Cutter
Director, Communicable Diseases Division
Singapore Ministry of Health
16 College Road
Singapore 169854

Christl A. Donnelly
MRC Centre for Outbreak Analysis and Modelling
Imperial College London
London, United Kingdom

Xavier de Lamballerie
UMR190, Aix-Marseille Univ - IRD - EHESP
French School of Public Health, Marseille, France
Koussay Dellagi
CRVOI (Centre de Recherche et de Veille sur les maladies émergentes dans l’Ocean Indien)
Plateforme CYROI, 2 Rue Maxime Riviere
97490 Sainte Clotilde, Ile de la Réunion

George Doukas
Senior Statistical Systems Officer, Centre for Epidemiology and Research
New South Wales Ministry of Health
73 Miller St, North Sydney NSW 2060, Australia

Sandra Dudareva-Vizule
Department for Infectious Disease Epidemiology
Robert Koch Institute
DGZ-Ring 1
D-13086 Berlin, Germany

Neil M Ferguson
MRC Centre for Outbreak Analysis and Modelling
Imperial College London
London, United Kingdom

Alicia M. Fry
Respiratory Diseases Branch, NCIRD
US Centers for Disease Control and Prevention
1600 Clifton RD NE, MS C-25
Atlanta, GA 30333, United States

Gwendolyn L. Gilbert
Centre for infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead NSW & Sydney Institute for Emerging Infectious Disease, University of Sydney, NSW, Australia

Walter Haas
Department for Infectious Disease Epidemiology
Robert Koch Institute
DGZ-Ring 1
D-13086 Berlin, Germany

Pia Hardelid
Statistics Unit
Centre for Infections, Health Protection Agency
London, United Kingdom

Peter Horby
Oxford University Clinical Research Unit & Wellcome Trust Major Overseas Programme Vietnam

Q. Sue Huang
Institute of Environmental Science and Research
National Centre for Biosecurity and Infectious Disease, Upper Hutt, New Zealand

Olav Hungnes
Department of Virology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
N-0403 Oslo, Norway

Niina Ikonen
Virology Unit, National Institute for Health and Welfare (THL)
Mannerheimintie 166, 00300 Helsinki, Finland

Kyoko Iwatsuki-Horimoto
Division of Virology
Department of Microbiology and Immunology
Institute of Medical Science University of Tokyo 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639, Japan

Ilkka Julkunen
Virology Unit, National Institute for Health and Welfare (THL)
Mannerheimintie 166, 00300 Helsinki, Finland

Jacqueline Katz
Respiratory Diseases Branch, NCIRD,
US Centers for Disease Control and Prevention
1600 Clifton RD NE, MS C-25,
Atlanta, GA 30333, United States

Yoshihiro Kawaoka
International Research Center for Infectious Diseases and Division of Virology Department of Microbiology and Immunology Institute of Medical Science University of Tokyo 4-6-1, Shirokanedai, Minato-ku Tokyo 108-8639, Japan
Ajit Lalvani  
Department of Respiratory Medicine,  
National Heart & Lung Institute,  
Wright Fleming Institute of Infection & Immunity,  
Imperial College, Norfolk Place  
London, United Kingdom

Daniel Levy-Bruhl  
Head of Vaccine Preventable Diseases Surveillance Unit  
Department of Infectious Diseases  
Institut de Veille Sanitaire  
12 rue du val d’Osne  
94415 Saint-Maurice Cedex  
France

Helena C. Maltezou  
Department for Interventions in Health-Care Facilities Hellenic Center for Disease Control and Prevention  
3-5 Agrafon Street  
Athens, 15123 Greece

Jodie McVernon  
Vaccine & Immunisation Research Group  
Murdoch Childrens Research Institute & Melbourne School of Population Health,  
The University of Melbourne,  
Parkville VIC 3010 Australia

Elizabeth Miller  
Immunisation Hepatitis and Blood Safety Department,  
Centre for Infections, Health Protection Agency,  
London, United Kingdom

AC Mishra  
National Institute of Virology  
20-A, Dr Ambedkar Road  
Pune 411001, India

Mohsen Moghadami  
Health Policy Research Center  
Shiraz University of Medical Sciences  
Shiraz, Iran

Shailesh D. Pawar  
National Institute of Virology  
20-A, Dr Ambedkar Road  
Pune 411001 India

Carrie Reed  
Respiratory Diseases Branch, NCIRD,  
US Centers for Disease Control and Prevention  
1600 Clifton RD NE, MS C-25,  
Atlanta, GA 30333, United States

Steven Riley  
MRC Centre for Outbreak Analysis and Modelling  
Imperial College London  
London, United Kingdom

Caterina Rizzo  
National Centre for Epidemiology, Surveillance and Health Promotion  
National Institute of Health (Istituto Superiore di Sanità ISS)  
Viale Regina Elena, 299  
00161 Rome Italy

Laura Rosella  
Public Health Ontario  
480 University Avenue, Suite 300  
Toronto, ON, Canada

Ted M. Ross  
University of Pittsburgh, Center for Vaccine Research  
Department of Microbiology and Molecular Genetics  
9047 BST3; 3501 Fifth Avenue  
Pittsburgh, PA 15261 USA

Yeulong Shu  
WHO Collaborating Center for Reference and Research on Influenza  
National Influenza Center of China  
National Institute for Viral Disease control and Prevention, China CDC  
155 Changbai Road, Changping District,  
Beijing, P.R. China

Danuta Skowronski  
Influenza & Emerging Respiratory Pathogens  
BC Centre for Disease Control  
Canada
References


15. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F,


38. Soh SE, Cook AR, Chen MIC, Lee VL, Chow VTK, Tee NWS, Lin RTP, Lim W-Y, Barr IG, Lin C, Vaidya S, Phoon MC, Ang LW, Sethi SK, Chia YC, Goh LG, Goh DLM, Tambyah PA, Thoon KC, Leo YS, Saw SM. Teacher led school-based surveillance can allow accurate tracking of
emerging infectious diseases – evidence from serial cross-sectional surveys of febrile respiratory illness during the H1N1 2009 influenza pandemic in Singapore. Influenza and Other Respiratory Viruses in press.


52. Chen M. personal communication, unpublished pediatric data.


